These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15781655)

  • 1. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
    Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
    Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin.
    Pepe A; Sun L; Zanardi I; Wu X; Ferlini C; Fontana G; Bombardelli E; Ojima I
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3300-4. PubMed ID: 19423340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
    Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
    Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
    Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
    Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular dynamics and tubulin polymerization kinetics study on 1,14-heterofused taxanes: evidence of stabilization of the tubulin head-to-tail dimer-dimer interaction.
    Contini A; Cappelletti G; Cartelli D; Fontana G; Gelmi ML
    Mol Biosyst; 2012 Oct; 8(12):3254-61. PubMed ID: 23073462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
    Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
    Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
    Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
    Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
    Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
    Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pocket similarity identifies selective estrogen receptor modulators as microtubule modulators at the taxane site.
    Lo YC; Cormier O; Liu T; Nettles KW; Katzenellenbogen JA; Stearns T; Altman RB
    Nat Commun; 2019 Mar; 10(1):1033. PubMed ID: 30833575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.
    Ganesh T; Yang C; Norris A; Glass T; Bane S; Ravindra R; Banerjee A; Metaferia B; Thomas SL; Giannakakou P; Alcaraz AA; Lakdawala AS; Snyder JP; Kingston DG
    J Med Chem; 2007 Feb; 50(4):713-25. PubMed ID: 17263521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
    Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
    Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.